Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adding Mitomycin to BCG for High-Risk Non-Muscle-Invasive Bladder Cancer
NCT02948543Phase 3Unknown
- Sponsor
- University of Sydney
- Start
- Jul 2013
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of mitomycin c in bladder cancer (2 arms), sponsored by University of Sydney. Primary endpoint: Disease free survival at 5 years. Status: unknown.
02
Drugs
mitomycin c
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02948543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948543.